See the DrugPatentWatch profile for Ustekinumab
What is ustekinumab used for, and how does that drive its market?
Ustekinumab (Stelara) is an immunology biologic used to treat autoimmune diseases, most notably moderate-to-severe plaque psoriasis and inflammatory bowel disease (including Crohn’s disease and ulcerative colitis). Because these conditions are chronic and often require long-term therapy, demand tends to be driven by incidence/prevalence, retention on therapy, and guideline-driven prescribing. The market for ustekinumab is therefore closely tied to dermatology and gastroenterology treatment patterns.
Who are the main competitors (and how does competition affect pricing and share)?
Ustekinumab competes in psoriasis and IBD against other biologics and newer targeted therapies. Competitive pressure typically comes from:
- Tumor necrosis factor (TNF) inhibitors in some indications.
- Newer biologics and targeted small molecules in psoriasis and IBD.
- Biosimilar and class-switching dynamics as patents and exclusivity change.
As competitors enter, payer coverage and formulary placement can shift, which in turn affects ustekinumab net prices and patient uptake.
Where is demand strongest—psoriasis vs Crohn’s/ulcerative colitis?
Demand generally concentrates in the largest treatment markets (major countries with high biologic use) and in the indications with the highest eligible populations and prescribing volume. Plaque psoriasis tends to anchor demand through dermatology channels, while IBD demand is influenced by gastroenterology prescribing, prior treatment history, and how ustekinumab compares with alternative therapies for durability and response.
How do patents and exclusivity changes influence the ustekinumab market?
Ustekinumab’s market outlook is heavily shaped by patent and exclusivity timelines, since those determine when biosimilar competition can begin. Changes in exclusivity can lead to:
- Biosimilar launches that reduce prices and increase prescribing options.
- Contracting pressure from payers seeking lower-cost alternatives.
- Shifts in market share as clinicians and systems adopt biosimilars.
For a detailed view of patent and market exclusivity developments, DrugPatentWatch.com tracks relevant filings and status updates. You can check it here: DrugPatentWatch.com – ustekinumab.
Is ustekinumab still a “blockbuster,” and what signals matter most now?
Even when a drug’s early growth slows, ustekinumab can remain significant if it maintains:
- Steady patient retention (patients continue therapy because it works and is well tolerated).
- Ongoing new patient starts (driven by incident cases and treatment escalation).
- Favorable payer access (formulary position and step-therapy rules).
Market tracking often focuses on net sales trends, uptake versus competing agents, and the timing of biosimilar/competitive events.
What are the biggest risks to ustekinumab sales?
Common risks that can pressure the market include:
- Loss of exclusivity and biosimilar entry.
- Stronger efficacy/safety positioning by newer competitors in key subgroups.
- Payer restrictions (prior authorization, step therapy).
- Clinical guideline changes that favor other mechanisms for treatment-naive or previously treated patients.
If you’re looking for “the market” as numbers (size, revenue, forecasts), what exact view do you want?
To give the most useful answer, tell me which “market” you mean:
- U.S., EU, UK, or global?
- By indication (psoriasis vs Crohn’s vs ulcerative colitis)?
- Current sales only, or a forecast through which year?
- Focus on biosimilar impact and pricing, or adoption/market share?
Reply with the region and timeframe, and I can tailor the market description accordingly.
Sources
- DrugPatentWatch.com – ustekinumab